<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75678">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02072044</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-06-IIB</org_study_id>
    <nct_id>NCT02072044</nct_id>
  </id_info>
  <brief_title>Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma（RCC）That Have Failed Or Are Intolerant To TKIs Therapy</brief_title>
  <official_title>A Phase II Study of Anlotinib(AL3818) Hydrochloric Capsule in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug
      Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing
      Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with
      multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance
      to new angiogenesis. The trial is to explore the efficacy and safety profile of Anlotinib in
      patients with advanced Renal Cell Carcinoma(RCC) that have failed to TKIs therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progress Free Survival (PFS)</measure>
    <time_frame>each 42 days up to PD or death (up to 36 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PFS time is defined as time from randomization to locoregional or systemic recurrence, second malignancy or death due to any cause; censored observations will be the last date of: &quot;death&quot;, &quot;last tumor assessment&quot;, &quot;last follow up date&quot; or &quot;last date in drug log&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 36 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the effectiveness of Anlotinib Hydrochloric Capsule by enhanced CT/MRI scan every two cycles. Objective Response Rate (ORR) is defined as participants who had complete response (CR) or partial response(PR) divided by the total number of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 36 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the effectiveness of Anlotinib Hydrochloric Capsule by enhanced CT/MRI scan every two cycles. Disease Control Rate (DCR) defined as the percentage of participants with Disease Control best overall response (complete response, partial response or stable disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization until death (up to 36 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS was defined as time from date of randomization to date of death due to any cause.  For participants still alive at the time of analysis, OS time was censored on last date that participants were known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Renal Cell Carcinoma（RCC）</condition>
  <arm_group>
    <arm_group_label>Anlotinib hydrochloric capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib hydrochloric capsule 12mg QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloric capsule</intervention_name>
    <description>Anlotinib 12 mg p.o. qd</description>
    <arm_group_label>Anlotinib hydrochloric capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Patients with histologically confirmed advanced renal cell carcinoma including
             clear cell component and not available for surgery

          -  2.Previously Failed Or Are Intolerant To TKIs Therapy(such as sunitinib, Sorafenib)

          -  3.With measurable disease (using RECIST1.1)

          -  4.18-75years,ECOG PS:0-1,Life expectancy of more than 3 months

          -  5.Last TKIs Therapy≥4 weeks

          -  6.Main organs function is normal

          -  7.Signed and dated informed consent

        Exclusion Criteria:

          -  1.patients has many influence factors toward oral medications

          -  2.Known brain metastases

          -  3.patients with severe and failed to controlled diseases,including: suboptimal blood
             pressure control;suffering from myocardial ischemia or above grade I myocardial
             infarction, arrhythmias and Class I heart failure;activity or failure to control
             severe infections;liver disease such as cirrhosis, decompensated liver disease,
             chronic active hepatitis;poorly controlled diabetes (FBG)&gt;10mmol/L);urine
             protein≥++,etc.

          -  4.patients failed to heal wounds or fractures for Long-term

          -  5.patients occurred venous thromboembolic events within 6 months

          -  6.patients has HIV-positive or organ transplantation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aiping Zhou, Doctor</last_name>
    <email>zhouap1825@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianhui Ma, Doctor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xu Zhang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanzhong Li, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhui Ma, Doctor</last_name>
    </contact>
    <contact_backup>
      <last_name>Aiping Zhou, Doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jianhui Ma, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aiping Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Luo, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gansu Province Tumor Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Li, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fangjian Zhou, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi medical university affiliated tumor hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianzhong Bai, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin medical university affiliated tumor hospital</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuxian Bai, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 81st Hospital of Chinese PLA</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yingxia Chen Chen, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>132000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Chen, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaodong Xie, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Province Tumor Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheng Fu, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital，Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiuwen Wang Wang, Doctor</last_name>
    </contact>
    <contact_backup>
      <last_name>Benkang Shi Shi, Doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>Xiuwen Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benkang Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qingdao Municial Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sichuan Hou, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dingwei Ye, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiyan Liu Liu, Dontor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiubao Ren, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/7545/renal-cancer/resources/1</url>
    <description>Renal Cancer</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/9339/kidney-cancer/resources/1</url>
    <description>Kidney Cancer</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/bye/uQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS90B7x061nuQoPmdt.</url>
    <description>Cancer</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Drug Information</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>January 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cell Carcinoma（RCC）</keyword>
  <keyword>Anlotinib</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
